25E-NBOMe is a synthetic psychedelic substance that belongs to the NBOMe series, a class of highly potent compounds structurally related to the 2C family. It was developed for research purposes and is known for its intense psychoactive effects at extremely low (microgram-level) doses. Derived from the 2C-E molecule, 25E-NBOMe is modified by the addition of a 2-methoxybenzyl group, which significantly increases its binding affinity to serotonin receptors—particularly 5-HT2A. Due to its potency, it is handled with great caution in laboratory environments and is strictly not for human consumption.

• Derived from 2C-E with N-Benzyl Modification
  25E-NBOMe is the N-(2-methoxybenzyl) derivative of 2C-E, meaning it retains the core structure of 2C-E but includes a modification that increases potency and receptor specificity.

• Acts as a 5-HT2A Receptor Agonist
  The compound primarily interacts with the serotonin 5-HT2A receptor, which is associated with hallucinations, sensory enhancement, and altered cognition—making it an important tool in receptor studies.

• Active at Microgram Levels
  Unlike many classical psychedelics that require milligram dosing, 25E-NBOMe is active at dosages as low as 250 micrograms, requiring precision equipment to handle safely.

• Used in Neuroscientific Research
  It is employed in experimental pharmacology and neuroscience to investigate the role of serotonin in perception, behavior, and consciousness.

• Highly Potent and Not for Human Use
  Even small miscalculations in dosage can lead to serious toxicity, making it unsuitable for unsupervised handling or recreational use.

• Produces Intense and Rapid Onset Effects
  Sublingual or buccal administration results in quick absorption, often leading to powerful visual distortions and cognitive shifts within 30–60 minutes.

• No Medical Use or Approval
  25E-NBOMe is not recognized for any therapeutic applications and remains a research-only substance.

The legal status of 25E-NBOMe is highly variable across jurisdictions. While some countries have explicitly banned it, others may regulate it under analogue laws or not list it at all, making its legality dependent on national and regional frameworks. Researchers and buyers must be fully aware of their local regulations before acquiring or handling this compound.

• Illegal Under Analogue Laws in the U.S.
  In the United States, while 25E-NBOMe is not federally scheduled by name, it is considered illegal under the Federal Analogue Act due to its similarity to 2C-E and its intended human consumption potential.

• Controlled in Many EU Member States
  Several European countries—such as Germany, Sweden, and the UK—have placed NBOMe compounds, including 25E-NBOMe, under strict regulation or Schedule I equivalents.

• Banned in Australia and Canada
  Australia classifies NBOMe substances as Schedule 9 (prohibited), and Canada also treats these compounds as controlled analogues under its analog drug regulations.

• Legal Grey Areas in Other Regions
  In some countries across Asia, Africa, or South America, 25E-NBOMe may remain unscheduled, allowing limited legal research under certain conditions.

• Subject to Import Restrictions
  Even in countries where it’s not explicitly banned, customs and postal authorities may seize packages based on suspicion or local psychoactive substance laws.

• Psycho Plug Uses Discreet International Shipping
  We employ stealth shipping methods to reduce customs interference but advise customers to confirm legal status before ordering.

• Buyers Hold Legal Responsibility
  It is the buyer’s duty to research their country’s legal framework regarding possession, importation, and research of 25E-NBOMe.

25E-NBOMe can appear in several physical forms depending on the intended method of administration and laboratory handling. Its appearance provides clues about its format, dosage, and potential use in research environments.

• Crystalline Powder
  When purchased in raw form, 25E-NBOMe typically appears as a fine, off-white to light beige crystalline powder. This powder is highly concentrated and must be handled with exact precision using a microgram scale.

• Blotter Paper Format
  For pre-measured dosing in research, the compound is often embedded in blotter paper sheets. These sheets may be plain or printed, each square typically holding 250–1000µg of active compound.

• Stable Under Controlled Storage
  In powder form, 25E-NBOMe is stable for up to two years when stored properly in sealed, dark, and dry containers away from air and moisture.

• Neutral or Slight Chemical Odor
  The compound may emit a faintly synthetic scent, especially when warmed or exposed to air, although it is generally odorless in sealed packaging.

• Packaged in Light-Proof Containers
  Psycho Plug provides the compound in UV-blocking, vacuum-sealed pouches or glass vials to preserve stability during shipping and storage.

• Air-Sensitive and Hygroscopic
  The powder may absorb moisture from the environment, so it must be kept in desiccant-lined containers if not immediately used.

• Visual Inspections Not a Substitute for Testing
  The appearance can help distinguish quality or contamination, but proper lab analysis remains essential to confirm identity and purity.

25E-NBOMe is known for its exceptional potency. Even the smallest variations in dose can result in dramatically different effects, which is why handling requires strict laboratory standards and equipment. Its effectiveness at sub-milligram doses distinguishes it from most other phenethylamine-based psychedelics.

• Effective at 250–1000 Micrograms
  The psychoactive threshold begins at roughly 250 µg, with full effects appearing from 500 µg to 1 mg. This high potency means that even trace quantities can produce significant outcomes.

• Stronger Than 2C-E
  Due to the added NBOMe group, it exhibits far greater affinity for the 5-HT2A receptor than its parent compound, 2C-E, requiring only a fraction of the dose.

• High Risk for Overdose Without Precision Tools
  Accurate dosing demands use of a microgram-precision scale. Eyeballing or using milligram tools risks dangerous overdosing, which has been documented in multiple case studies.

• Potency Leads to Intense Peak Effects
  At active doses, the compound can induce overwhelming visual phenomena, emotional variability, and ego dissolution—effects that must be studied with caution.

• Increased Receptor Binding Affinity
  The NBOMe structure dramatically enhances serotonin receptor activity, making it a preferred candidate for 5-HT2A receptor research and modeling.

• Rapid Onset Through Sublingual Absorption
  Its high potency also enables faster onset when administered sublingually, bypassing first-pass metabolism and increasing bioavailability.

• Unsafe for Human Use Despite Microgram Effectiveness
  Despite its strong potency, 25E-NBOMe is strictly for chemical and receptor binding studies—never for consumption or uncontrolled application.

25E-NBOMe produces a range of powerful psychedelic effects that have been documented in controlled laboratory studies, self-reported case files, and receptor research. These effects occur primarily through serotonergic activity, especially at the 5-HT2A site. Due to its high potency, these effects can be unpredictable without highly controlled conditions.

• Intense Visual Hallucinations
  Users under supervised settings have reported complex geometric patterns, enhanced color perception, light trails, and object distortion, typically beginning within 30–60 minutes.

• Ego Dissolution and Cognitive Alteration
  The compound can temporarily dissolve the sense of self, distort thought patterns, and induce philosophical or introspective episodes, making it a subject of consciousness research.

• Emotional Amplification
  Both positive and negative emotions may become intensified. This emotional volatility is a risk factor in unsupervised environments and necessitates psychological safeguards in research.

• Time Dilation and Temporal Looping
  Altered perception of time is frequently reported, with minutes feeling like hours. This can complicate cognitive tasks and self-monitoring during research experiments.

• Physical Sensations and Stimulation
  Common somatic effects include muscle tension, jaw clenching, pupil dilation, tactile sensitivity, and increased heart rate.

• Possible Vasoconstriction or Hypertension
  In higher doses or vulnerable individuals, 25E-NBOMe may trigger vascular narrowing and elevated blood pressure, which are critical to monitor in any physiological studies.

• High Variability Based on Set and Setting
  The effects are highly context-dependent. Variables such as environment, mental state, and concurrent stimuli influence the depth and direction of the experience.

25E-NBOMe is known for its low oral bioavailability, meaning it is largely ineffective when swallowed. To ensure absorption, it must be administered through routes that bypass first-pass metabolism. In laboratory settings, researchers apply specific methods for accuracy, safety, and efficacy, especially when studying receptor activation or behavioral responses.

• Sublingual Administration (Under the Tongue)
  The most common method for 25E-NBOMe delivery is placing it under the tongue, where it is absorbed through the mucous membranes. This allows the compound to enter the bloodstream directly, bypassing the liver.

• Buccal Administration (Inside the Cheek)
  An alternative to sublingual use is buccal administration, where the substance is placed between the gum and cheek. This method offers comparable absorption and is often used in pharmacokinetic studies.

• Blotter Paper Dosing
  Due to its microgram-level potency, 25E-NBOMe is often dissolved into an ethanol solution and infused into blotter paper. This allows for accurate, pre-measured dosages that are easier to administer in controlled studies.

• Powder Form Handling in Lab Settings
  The raw powder can be measured using an analytical microbalance and dissolved in a solvent like ethanol for sublingual administration or receptor binding assays.

• Ineffectiveness via Oral Ingestion
  Swallowing 25E-NBOMe is ineffective for psychoactive or receptor-binding studies, as the liver quickly breaks it down. Oral ingestion results in extremely low bioavailability and is discouraged in any research context.

• Intranasal Use (Less Common in Research)
  Some researchers have explored intranasal administration; however, this method increases risk of mucosal damage and inconsistent absorption, making it less preferred.

• Transdermal and Inhalation Not Recommended
  These methods are either ineffective or highly unsafe for 25E-NBOMe and are not employed in any credible research practice.

Due to its extreme potency and physiological risks, 25E-NBOMe demands stringent safety measures when handled in any research or analytical context. Inappropriate handling can lead to accidental exposure, which may result in severe physical or psychological effects. All laboratories working with NBOMe-class compounds must adhere to professional-grade chemical safety protocols.

• Use of a Precision Microgram Scale
  Doses must be weighed using a microbalance accurate to 0.0001 grams. Even slight overestimation can result in serious physiological effects, making accurate measurement essential.

• Gloves, Eye Protection, and Lab Coats
  Always wear nitrile gloves, protective eyewear, and full-body lab garments. The compound can be absorbed through skin and mucous membranes, posing a risk even in small amounts.

• Avoid Airborne Exposure
  Work with the powder inside a fume hood or a sealed environment to prevent accidental inhalation of particles, especially during preparation of solutions or blotters.

• Clearly Labeled Containers and Storage
  Store 25E-NBOMe in well-labeled, airtight containers, ideally amber glass or opaque plastic to prevent degradation and accidental misuse.

• No Handling Near Food or Drink
  Ensure the workspace is sterile and free from food, drink, or personal items. Contamination of personal items could result in unintended exposure.

• Proper Disposal Protocols
  Follow local and international guidelines for disposing of psychoactive compounds. Never discard NBOMe solutions or powders in regular waste systems.

• Keep Away from Unauthorized Individuals
  Limit access to only trained professionals. Accidental exposure or misuse by untrained personnel can result in severe or life-threatening consequences.

Although 25E-NBOMe is chemically related to 2C-E, they are not the same substance. 25E-NBOMe is derived from 2C-E but has been structurally modified to enhance potency and receptor binding. The two compounds differ in their dosage, effects, legal status, and applications in research.

• 2C-E is the Precursor Molecule
  25E-NBOMe is created by adding a 2-methoxybenzyl group to the amine of 2C-E. This alteration increases its lipophilicity and allows for stronger serotonin receptor binding.

• Potency is Significantly Higher in 25E-NBOMe
  While 2C-E is typically active at 10–25 mg, 25E-NBOMe is active at just 250–1000 µg. This makes NBOMe versions over 10 times more potent.

• Different Routes of Administration
  2C-E is effective when ingested orally, while 25E-NBOMe must be administered sublingually or buccally due to poor oral bioavailability.

• Effects Can Differ in Intensity and Duration
  25E-NBOMe tends to produce sharper visuals, a faster onset, and more intense physical stimulation compared to the more gradual and introspective effects of 2C-E.

• Legal Status May Differ
  In many jurisdictions, 2C-E and 25E-NBOMe are scheduled differently. Some countries ban one but not the other, depending on how analog laws are enforced.

• Risk Profile is Higher with 25E-NBOMe
  The margin of error is much narrower with 25E-NBOMe. Overdoses are more likely and more dangerous compared to the relatively broader dose range of 2C-E.

• Receptor Binding Characteristics Differ
  While both act on serotonin receptors, 25E-NBOMe has a higher binding affinity for 5-HT2A, making it more suitable for targeted receptor studies.

While 25E-NBOMe is valuable in research, it carries significant health and safety risks—particularly if mishandled or misused. Reports of adverse reactions and fatalities related to NBOMe compounds have been documented, largely due to improper dosage or unsupervised use. It is essential to understand and mitigate these risks in any research environment.

• Extremely Narrow Safety Margin
  The difference between a threshold dose and a toxic dose is very small. An accidental overdose can lead to seizures, psychosis, or death.

• Vasoconstriction and Cardiovascular Strain
  25E-NBOMe is known to cause blood vessel constriction, which may result in elevated blood pressure, chest pain, and increased risk of stroke or cardiac arrest.

• Severe Psychological Effects
  High doses or unsupervised settings may cause panic attacks, paranoia, suicidal ideation, or full dissociation, making it dangerous outside controlled environments.

• Neurological Impact
  In sensitive individuals or at high doses, 25E-NBOMe can trigger seizures, serotonin syndrome, or prolonged confusion, especially when combined with other drugs.

• Risk of Tissue Damage via Improper Administration
  Intranasal or intravenous misuse may result in nasal lining erosion, tissue necrosis, or systemic toxicity due to uneven distribution or impurities.

• High Potential for Misidentification
  Without rigorous lab analysis, 25E-NBOMe may be confused with less potent compounds, leading to accidental overdosing.

• No Known Antidote or Clinical Antagonist
  In case of overdose, medical support is limited to symptomatic treatment. There is no specific reversal agent for NBOMe toxicity.

To maintain its chemical stability, potency, and safety, 25E-NBOMe must be stored under strict laboratory conditions. Incorrect storage can lead to degradation, contamination, or unintentional exposure, which can compromise both research outcomes and safety.

• Cool, Dark, and Dry Environment
  The compound should be stored in an environment under 20°C, away from direct sunlight, humidity, and air exposure. Light and moisture can degrade its structure over time.

• Use of Airtight, UV-Resistant Containers
  Amber glass vials or light-proof polymer containers are ideal for preventing degradation due to ultraviolet radiation and oxygen.

• Vacuum-Sealed Packaging for Long-Term Storage
  When stored for months or years, vacuum-sealed or nitrogen-flushed bags prevent oxidation and contamination, ensuring the compound remains stable.

• Clearly Labeled with Chemical Identity and Date
  Labels should include compound name, batch number, concentration (if in solution), and date of acquisition to track usage and expiration.

• Separate from Other Chemicals
  Store separately from volatile solvents, acids, and reactive agents to avoid cross-contamination or dangerous reactions.

• Keep in a Secure, Access-Controlled Area
  Due to its psychoactive nature, 25E-NBOMe should be stored in a locked chemical cabinet or restricted-access freezer.

• Do Not Store in Areas Prone to Fluctuations
  Avoid placing in fridges, cupboards, or lab drawers that experience temperature or humidity changes. Stability is best preserved under constant, controlled conditions.

The chemical structure of 25E-NBOMe is what gives it its exceptionally high affinity for serotonin receptors and its potency at microgram levels. As a modified derivative of 2C-E, 25E-NBOMe includes a unique N-(2-methoxybenzyl) substitution that enhances its pharmacological properties. Its structure is critical for understanding both its action and its place in the NBOMe series of psychedelics.

• IUPAC Name
  The full chemical name is 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. This reflects both the core phenethylamine structure and the NBOMe modification.

• Molecular Formula and Weight
  25E-NBOMe has the molecular formula C20H27NO3, with a molecular mass of 353.45 g/mol, which is slightly higher than 2C-E due to the added methoxybenzyl group.

• N-Benzyl Substitution on the Amine
  The defining feature of NBOMe compounds is the substitution of a 2-methoxybenzyl group on the nitrogen of the primary amine. This modification significantly increases lipophilicity and enhances receptor binding.

• Substituted Phenethylamine Backbone
  The core of 25E-NBOMe is based on the 2C-E molecule, itself a 2,5-dimethoxy-4-ethylphenethylamine, which contributes to its hallucinogenic properties.

• Three Key Functional Groups
  The structure contains three methoxy groups—two on the aromatic ring (positions 2 and 5) and one on the N-benzyl ring—contributing to serotonin receptor activity.

• Chiral but Used as Racemate
  While the molecule is chiral, it is typically synthesized and distributed as a racemic mixture (equal parts of both enantiomers) in research settings.

• Non-Scheduled CAS Number
  As of now, 25E-NBOMe does not have an officially assigned CAS number, reflecting its classification as a research chemical rather than a recognized pharmaceutical compound.

Standard drug testing panels do not typically include 25E-NBOMe, meaning it often goes undetected in routine screenings. However, with specialized equipment and targeted testing, it can be identified in both biological samples and forensic investigations. Whether or not it appears on a test depends heavily on the context and the laboratory’s capabilities.

• Not Included in Standard 5- or 10-Panel Tests
  Employment, legal, or rehab-related drug screenings usually test for substances like THC, cocaine, opiates, amphetamines, and benzodiazepines—not NBOMe compounds.

• Detectable with Advanced Analytical Methods
  Techniques such as gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–mass spectrometry (LC-MS) can identify 25E-NBOMe with high specificity when targeted.

• Used in Forensic Toxicology
  In cases of overdose or death, forensic laboratories may test for NBOMe compounds using sensitive methods, particularly if the compound is suspected.

• Short Detection Window in Blood
  25E-NBOMe is rapidly metabolized in the body, making it detectable in blood for a limited time (often less than 24 hours post-administration).

• Urine Testing Is More Viable with Targeted Panels
  If tested specifically, its metabolites can be detected in urine, usually within 1 to 3 days of use depending on dose and metabolism.

• No Known Cross-Reactivity with LSD or MDMA Tests
  The compound is chemically distinct and does not cause false positives for more commonly tested psychedelics like LSD or MDMA.

• Specialty Labs May Offer NBOMe Screening
  Certain private labs, especially those focused on toxicology or harm reduction, may offer NBOMe panel testing on request.

Despite its high potency, 25E-NBOMe is not recommended for microdosing and is not considered safe or suitable for such practices. Microdosing typically involves sub-perceptual dosing of psychedelics for therapeutic or cognitive enhancement purposes, but NBOMe compounds present several factors that make them inappropriate for this use.

• Extremely Narrow Therapeutic Window
  The difference between a microdose and a full active dose of 25E-NBOMe is so small that accurate, safe dosing is virtually impossible without highly sensitive lab equipment.

• High Risk of Overdose
  Even a minor error in measuring a microdose could lead to a full-blown psychedelic experience or toxic reaction. This risk negates the basic premise of microdosing safety.

• Unpredictable Effects at Low Doses
  There is no reliable data on how 25E-NBOMe behaves at sub-threshold doses. Some users report no effects, while others report strong stimulation or anxiety.

• Lack of Therapeutic Research
  Unlike LSD or psilocybin, 25E-NBOMe has not been studied in clinical settings for microdosing applications. No evidence supports its long-term safety or benefits in this context.

• Potential for Psychological Instability
  Even at very low doses, NBOMe compounds can sometimes produce unease, restlessness, or cognitive fog, defeating the purpose of microdosing.

• Not Designed for Regular Ingestion
  The compound’s chemical structure and unknown metabolite profile raise concerns about repeated use over time, especially in uncontrolled environments.

• Ethical and Legal Complications
  Attempting to microdose with a compound that is not approved for human use and may be banned locally introduces significant legal and medical risks.

The effects of 25E-NBOMe are known to be long-lasting, with distinct phases that unfold over several hours. The exact duration depends on factors such as dosage, route of administration, individual metabolism, and environmental context. Researchers must account for these phases when designing experiments or observing subject responses.

• Onset Within 30–60 Minutes (Sublingual/Buccal)
  When absorbed through mucous membranes, the first noticeable effects generally begin within 30 minutes, gradually intensifying as peak approaches.

• Peak Effects Occur Between 1.5 and 3 Hours
  During this time, subjects may experience the most profound sensory and cognitive alterations. This is the critical phase for receptor-binding or neurobehavioral studies.

• Plateau Phase Lasts 2–4 Hours
  The effects remain relatively stable during this period, though intensity may vary depending on dose and tolerance. Researchers typically observe consistent patterns of reaction during this phase.

• Gradual Decline Over 2–4 Additional Hours
  The effects taper off slowly, often accompanied by fatigue, residual visuals, or mild confusion as normal perception returns.

• Total Duration Around 6–10 Hours
  From onset to full return to baseline, most experiences last between 6 to 10 hours, though some aftereffects may linger slightly longer.

• Aftereffects May Include Insomnia or Mental Fatigue
  Residual stimulation may interfere with sleep or concentration for several hours after the primary effects wear off.

• Duration May Vary with Individual Physiology
  Liver enzyme activity, previous psychedelic experience, and concurrent substance use can influence how long the effects persist.

No, 25E-NBOMe is not considered safe for beginners or those without extensive experience handling potent psychoactive compounds. Its extreme potency, narrow safety margin, and high potential for adverse reactions make it unsuitable for anyone lacking proper training and equipment. Even seasoned researchers approach it with caution.

• Risk of Overdose is High for Inexperienced Users
  Beginners may underestimate its strength or mishandle the microgram dosing, resulting in dangerous physical or psychological outcomes.

• Difficult to Measure Without Specialized Equipment
  Analytical balances capable of weighing micrograms are required for safe handling. Beginners often lack access to or knowledge of how to use these devices properly.

• Unpredictable Effects in Novice Subjects
  Psychological reactions such as panic, confusion, or hallucination-induced distress are more likely in individuals unfamiliar with strong serotonergic compounds.

• High Likelihood of Negative Set and Setting
  Inadequate mental preparation, inappropriate environment, or lack of understanding about the compound’s nature can exacerbate risks.

• Not Recommended for Any Form of Self-Experimentation
  Given its unsuitability for human use, attempts to self-administer—even in a research context—can have life-threatening consequences.

• Better Alternatives for New Researchers
  Compounds with a broader safety profile and lower potency, such as 2C-B or 1P-LSD, are typically preferred for beginners conducting early-stage studies.

• Requires Full Understanding of Laboratory Safety Protocols
  Without a firm grasp of chemical handling, hazard labeling, and emergency planning, beginners should not work with NBOMe-class substances.